See the DrugPatentWatch profile for Linzess
Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) [1]. The active ingredient in Linzess is linaclotide [2]. Linaclotide is a guanylate cyclase-C (GC-C) agonist that works locally in the small intestine to help relieve abdominal pain and improve bowel movements [3][4].
What is Linaclotide?
Linaclotide is a peptide that acts on the guanylate cyclase-C receptor present on the luminal surface of the intestinal epithelium. Activation of this receptor increases cyclic guanosine monophosphate (cGMP), which stimulates fluid secretion and accelerates intestinal transit [3][5].
What are the inactive ingredients in Linzess?
In addition to linaclotide, Linzess capsules contain several inactive ingredients. These include hypromellose, microcrystalline cellulose, and potassium perchlorate [2]. The capsule shell is made of hypromellose, titanium dioxide, and pharmaceutical ink [2].
How does Linzess work to treat constipation?
Linzess works by targeting the underlying mechanisms of IBS-C and CIC. By activating the GC-C receptor, it increases the amount of water in the intestines, which softens the stool and promotes bowel movements. It also helps to reduce the sensitivity of visceral nerves, which can alleviate abdominal pain associated with IBS-C [4][5].
When does the patent for Linzess expire?
Information regarding the specific patent expiry dates for Linzess is available through specialized patent tracking resources. DrugPatentWatch.com provides detailed information on drug patents, including their expiry [6].
What are the potential side effects of Linzess?
The most common side effect of Linzess is diarrhea [1]. Other potential side effects include abdominal pain, flatulence, and nausea [1][4]. Patients are advised to contact their doctor if they experience severe or persistent diarrhea [1].